Rocuronium
Circulating Tumor Cells
Zhejiang Cancer HospitalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Circulating Tumor Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Zhejiang Cancer Hospital | Phase 4 | BBB |
TRASTUZUMAB European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | B |
PROPOFOL Zhejiang Cancer Hospital | Phase 2 | B |
Docetaxel UNICANCER | Phase 2 | B |
CABAZITAXEL UNICANCER | Phase 2 | B |
Acetylsalicylic Acid Zhejiang Provincial People's Hospital | Phase 2 | CCC |
Same molecule, other indications
Rocuronium is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →